A detailed history of Bank Of America Corp transactions in Kodiak Sciences Inc. stock. As of the latest transaction made, Bank Of America Corp holds 263,602 shares of KOD stock, worth $1.53 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
263,602
Previous 295,156 10.69%
Holding current value
$1.53 Million
Previous $693,000 0.72%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$2.2 - $3.25 $69,418 - $102,550
-31,554 Reduced 10.69%
263,602 $688,000
Q2 2024

Aug 14, 2024

BUY
$2.29 - $4.48 $18,645 - $36,476
8,142 Added 2.84%
295,156 $693,000
Q1 2024

May 15, 2024

BUY
$3.01 - $7.45 $654,903 - $1.62 Million
217,576 Added 313.34%
287,014 $1.51 Million
Q4 2023

Feb 14, 2024

BUY
$1.4 - $3.24 $28,155 - $65,159
20,111 Added 40.77%
69,438 $211,000
Q2 2023

Aug 14, 2023

BUY
$4.3 - $9.48 $41,993 - $92,581
9,766 Added 24.69%
49,327 $340,000
Q1 2023

May 12, 2023

SELL
$4.81 - $8.88 $30,553 - $56,405
-6,352 Reduced 13.83%
39,561 $245,000
Q4 2022

Feb 10, 2023

SELL
$6.52 - $8.05 $146,537 - $180,923
-22,475 Reduced 32.86%
45,913 $328,000
Q3 2022

Nov 14, 2022

SELL
$7.57 - $12.5 $93,799 - $154,887
-12,391 Reduced 15.34%
68,388 $530,000
Q2 2022

Aug 12, 2022

BUY
$5.04 - $9.48 $26,293 - $49,457
5,217 Added 6.9%
80,779 $617,000
Q1 2022

May 16, 2022

BUY
$7.09 - $89.45 $101,387 - $1.28 Million
14,300 Added 23.34%
75,562 $583,000
Q4 2021

Feb 08, 2022

BUY
$80.85 - $128.49 $2.58 Million - $4.1 Million
31,889 Added 108.57%
61,262 $5.19 Million
Q3 2021

Nov 15, 2021

SELL
$81.97 - $106.94 $2.54 Million - $3.31 Million
-30,975 Reduced 51.33%
29,373 $2.82 Million
Q2 2021

Sep 13, 2021

BUY
$77.2 - $126.54 $4.66 Million - $7.64 Million
60,348 New
60,348 $5.61 Million

Others Institutions Holding KOD

About Kodiak Sciences Inc.


  • Ticker KOD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 52,040,200
  • Market Cap $301M
  • Description
  • Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as we...
More about KOD
Track This Portfolio

Track Bank Of America Corp Portfolio

Follow Bank Of America Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.